Obagi Medical Partners with Schweiger to Launch Phase 4 saypha MagIQ Program
Waldencast’s Obagi Medical launched the ALOHA Program with Schweiger Dermatology to drive real-world evidence for its saypha MagIQ injectable through a Phase 4 study and an evaluation program beginning early 2026 across Schweiger’s network. The partnership aims to translate FDA pivotal trial results into everyday practice and strengthen provider-patient relationships.
1. Partnership Overview
Waldencast’s Obagi Medical has selected Schweiger Dermatology as its key partner for the ALOHA Program to generate real-world evidence for Obagi® saypha® MagIQ™. Schweiger’s commitment to clinical excellence, rapid patient access and extensive practice network underpins the collaboration.
2. Program Details
The ALOHA Program encompasses a Phase 4 clinical study led by Dr. David Goldberg at Schweiger’s Hackensack location and a real-world evaluation at select high-performing Schweiger aesthetic sites. Activities begin in early 2026 and include standardized data capture and hands-on provider experience with integrated Obagi protocols.
3. Strategic Implications
The collaboration aims to translate FDA pivotal trial safety and efficacy results into everyday practice and drive adoption of Obagi® saypha® MagIQ™. Waldencast expects the program to strengthen provider-patient relationships, support a differentiated launch strategy and showcase category-leading performance of the injectable.